RLS-0071 is ReAlta’s lead dual-action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic ischemic encephalopathy,...
Read MoreNorfolk, VA, June 1st, 2022 – ReAlta Life Sciences, Inc. (“ReAlta”) a clinical stage, rare disease company addressing life-threatening diseases...
Read MoreInhaled LPS Challenge Trial to Support Development of RLS-0071 in Severe Asthma RLS-0071 is ReAlta’s lead dual action complement inhibitor...
Read MoreReAlta Life Sciences, Inc. (“ReAlta”) a clinical stage, rare disease company addressing life-threatening diseases through harnessing the power of the...
Read MoreNorfolk, VA, April 5, 2022 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive...
Read MoreRLS-0071 is a dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic-ischemic encephalopathy and...
Read MoreRLS-0071 is ReAlta’s lead dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic-ischemic encephalopathy...
Read MorePresenting first-in-human trial data in healthy volunteers of RLS-0071, the Company’s dual action complement inhibitor and innate anti-inflammatory product candidate...
Read MoreNorfolk, VA, February 22, 2022 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer is scheduled...
Read More